Somatrem
Somatrem is a recombinant human growth hormone preparation that includes an additional methionine residue at the N-terminus compared to native pituitary-derived GH, used to treat growth failure due to growth hormone deficiency in children. Like endogenous GH, it binds to GH receptors to stimulate IGF-1 production, linear bone growth, and protein anabolism. It has largely been replaced by somatropin, which has the identical amino acid sequence to native human GH.
Peso Molecular
1009,1000 g/mol
LogP
-6,40
TPSA
452,00 Ų
Regra dos 5 de Lipinski
Reprovado
Mecanismo de Ação
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
SMILES
C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N)NC(=O)[C@H](C(C)C)N
InChI
InChI=1S/C43H72N14O14/c1-21(2)33(44)40(69)51-23(5)36(65)55-34(22(3)4)41(70)49-19-29(58)52-25(12-14-31(60)61)37(66)54-26(13-15-32(62)63)42(71)57-18-8-10-27(57)38(67)50-20-30(59)56-17-7-11-28(56)39(68)53-24(35(45)64)9-6-16-48-43(46)47/h21-28,33-34H,6-20,44H2,1-5H3,(H2,45,64)(H,49,70)(H,50,67)(H,51,69)(H,52,58)(H,53,68)(H,54,66)(H,55,65)(H,60,61)(H,62,63)(H4,46,47,48)/t23-,24-,25-,26-,27-,28-,33-,34-/m0/s1
Molecular Formula
C43H72N14O14
HBD / HBA
13 / 16
Ligações Rotacionáveis
29
Átomos Pesados
71
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Somatrem is a recombinant human growth hormone preparation that includes an additional methionine residue at the N-terminus compared to native pituitary-derived GH, used to treat growth failure due to growth hormone deficiency in children. Like endogenous GH, it binds to GH receptors to stimulate IGF-1 production, linear bone growth, and protein anabolism. It has largely been replaced by somatropin, which has the identical amino acid sequence to native human GH.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Somatrem is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201620. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5487805. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="somatrem"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/somatrem/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/somatrem/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/somatrem/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="somatrem"></drugfyi-drug>